Biotech IV Monitor

MDGL — Madrigal Pharmaceuticals Inc.

$12.5B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for Madrigal Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts53 Phase 3
Market cap$12.5B
Cash & investments$961Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-03

Upcoming readouts

Phase 3 Resmetirom
NASH; Cirrhosis, Liver · NCT05500222
December 2026
Ongoing
Phase 3 Resmetirom
Non-Alcoholic Fatty Liver Disease · NCT04951219
March 2027
Ongoing
Phase 3 MGL-3196
NASH - Nonalcoholic Steatohepatitis · NCT03900429
January 2028
Ongoing
Phase 2 Resmetirom
MASH - Metabolic Dysfunction-Associated Steatohepatitis · NCT07335601
August 2028
Recruiting
Phase 2 Resmetirom
MASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis · NCT07763015
July 2029
Recruiting

Cash position

Madrigal Pharmaceuticals Inc. reported $961M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). It reported net income of $55M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-03

Companies working on similar indications

Discussion

No messages yet. If you follow MDGL, you can start the conversation.
Track MDGL in real time
See live implied volatility for MDGL and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on MDGL
Contact — questions or corrections about MDGL: dukeupt@gmail.com